What is the address of PROBELPHARMA?

The registered office of PROBELPHARMA is located at Gulpen 327, 4852 Plombières.

Is PROBELPHARMA still active?

Yes. According to the CBE (29 October 2026) PROBELPHARMA is active, legal situation “Normale toestand”, started on 15 March 2000.

Is PROBELPHARMA registered on Peppol?

No, PROBELPHARMA is currently not registered on the Peppol network.

What is the enterprise number of PROBELPHARMA?

The enterprise number of PROBELPHARMA is BE0471439893.

When was PROBELPHARMA founded?

PROBELPHARMA was founded on 15 March 2000.

Who are the directors of PROBELPHARMA?

According to the 2025 annual accounts, the directors of PROBELPHARMA are: Richard Bolly, Christiane Noel, Marc Crepel, Nikolaus Reul, Benoit Renard.

Is PROBELPHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 15 March 2000; 5 annual accounts filed, latest fiscal year 2025; 5 directors known from the annual account.

How much profit did PROBELPHARMA make in 2025?

PROBELPHARMA recorded a loss after taxes of € 3,556 in financial year 2025.

What is the revenue of PROBELPHARMA?

As a small company, PROBELPHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -3,881.

PROBELPHARMA (Private Limited) - Plombières

Dossier PROBELPHARMA, printed on 29 October 2026 from databakkes.be/en/0471439893/probelpharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Two loss years in a row NBB

Negative result in 2024 and 2025.
Tight liquidity NBB

Cash and receivables cover 3 % of short-term debt in 2025; threshold 65 %.
Not on Peppol Peppol

Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.

Financials

Financial year 2025

PROBELPHARMA from Plombières, company number BE0471439893, closed financial year 2025 with a result of € -3,556 after tax. For that financial year PROBELPHARMA recorded a gross margin of € -3,881 and equity of € 120,358. Compared with financial year 2024, the result moved from € -3,384 to € -3,556. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 26, 2026.

What it is worth Healthy

€ 120,358

▼ 3% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -3,556

▼ 5 % more loss than in 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 5,514

▼ 37% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 103,877.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 740

▲ 90% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ -9,420 Gross margin 2022: € -9,420 First fiscal year in the series	€ -3,483 Gross margin 2023: € -3,483 ▲ € 5,937 vs 2022 (€ -9,420) Favourable step	€ -3,265 Gross margin 2024: € -3,265 ▲ € 218 vs 2023 (€ -3,483) Favourable step	€ -3,881 Gross margin 2025: € -3,881 ▼ € 616 vs 2024 (€ -3,265) Unfavourable step	▼ € 616
Profit after taxes	€ -10,837 Profit after taxes 2022: € -10,837 First fiscal year in the series	€ -8,904 Profit after taxes 2023: € -8,904 ▲ € 1,934 vs 2022 (€ -10,837) Favourable step	€ -3,384 Profit after taxes 2024: € -3,384 ▲ € 5,519 vs 2023 (€ -8,904) Favourable step	€ -3,556 Profit after taxes 2025: € -3,556 ▼ € 172 vs 2024 (€ -3,384) Unfavourable step	▼ € 172
Equity	€ 136,202 Equity 2022: € 136,202 First fiscal year in the series	€ 127,298 Equity 2023: € 127,298 ▼ 7% vs 2022 (€ 136,202) Unfavourable step	€ 123,914 Equity 2024: € 123,914 ▼ 3% vs 2023 (€ 127,298) Unfavourable step	€ 120,358 Equity 2025: € 120,358 ▼ 3% vs 2024 (€ 123,914) Unfavourable step	▼ 3%
Total debts	€ 172,145 Total debts 2022: € 172,145 First fiscal year in the series	€ 179,482 Total debts 2023: € 179,482 ▲ 4% vs 2022 (€ 172,145) Unfavourable step	€ 172,364 Total debts 2024: € 172,364 ▼ 4% vs 2023 (€ 179,482) Favourable step	€ 172,714 Total debts 2025: € 172,714 Unchanged (€ 172,364) Unfavourable step
Cash	€ 22,276 Cash 2022: € 22,276 First fiscal year in the series	€ 19,222 Cash 2023: € 19,222 ▼ 14% vs 2022 (€ 22,276) Unfavourable step	€ 8,719 Cash 2024: € 8,719 ▼ 55% vs 2023 (€ 19,222) Unfavourable step	€ 5,514 Cash 2025: € 5,514 ▼ 37% vs 2024 (€ 8,719) Unfavourable step	▼ 37%
Retained profit	€ 119,721 Retained profit 2022: € 119,721 First fiscal year in the series	€ 110,817 Retained profit 2023: € 110,817 ▼ 7% vs 2022 (€ 119,721) Unfavourable step	€ 107,433 Retained profit 2024: € 107,433 ▼ 3% vs 2023 (€ 110,817) Unfavourable step	€ 103,877 Retained profit 2025: € 103,877 ▼ 3% vs 2024 (€ 107,433) Unfavourable step	▼ 3%
Balance sheet total	€ 308,347 Balance sheet total 2022: € 308,347 First fiscal year in the series	€ 306,780 Balance sheet total 2023: € 306,780 ▼ 1% vs 2022 (€ 308,347) Unchanged	€ 296,278 Balance sheet total 2024: € 296,278 ▼ 3% vs 2023 (€ 306,780) Unchanged	€ 293,072 Balance sheet total 2025: € 293,072 ▼ 1% vs 2024 (€ 296,278) Unchanged	▼ 1%

Key figures of PROBELPHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PROBELPHARMA?

What happened at PROBELPHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

2027 Richard Bolly stepped down as director. NBB
2027 Christiane Noel stepped down as director. NBB
2027 Nikolaus Reul stepped down as director. NBB
2027 Benoit Renard stepped down as director. NBB
Jun 26, 2026 New annual accounts for financial year 2025: loss of € 3,556. Source: NBB ↗
2025 Marc Crepel stepped down as director. NBB
2021 Richard Bolly became a director. NBB
2021 Christiane Noel became a director. NBB

In short

From € 10,837 loss in 2022 to € 3,556 loss in 2025.

Original PDFs at the National Bank ↗

Management

Directors

According to the 2025 annual accounts

Richard Bolly

Managing director

Also active at: FERME SAINT GEORGES

since 2021 · until 2027

Christiane Noel

Director

Also active at: Pouvoir Organisateur du Parc naturel des deux Ourthes asbl

since 2021 · until 2027

Marc Crepel

Director

since 2021 · until 2025

Nikolaus Reul

Director

Also active at: APOTHEKE REUL

since 2021 · until 2027

Benoit Renard

Director

Also active at: PHARMACIE RENARD, PHARMACIE THAUVIN

since 2021 · until 2027

Establishments

Establishment units

Physical locations of this company

Registered office

Gulpen 327

4852 Plombières

2.116.068.460

Schurhoven 3149

3800 Sint-Truiden

Active since 5 December 2000

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

FERME SAINT GEORGES same network

€ 63,982 gross margin · 2025

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0471.439.893
VAT number: BE 0471.439.893
Registered office: Gulpen 327, 4852 Plombières
Names & denominations: PROBELPHARMA
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 15 March 2000
Peppol: Not registered

View on CBE Public ↗ Annual accounts (NBB) ↗

PROBELPHARMA

Warning lights

Financials

What happened to PROBELPHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions